15th week of 2011 patent applcation highlights part 23 |
Patent application number | Title | Published |
20110085998 | Mascara Composition - Mascara compositions containing a keratin conditioning agent, alone or in combination with an emollient/moisturizing agent, provide increased resistance of eyelash hair fibers to breaking. Low viscosity mascara composition of the invention containing low concentrations of surfactant and wax are easily removable from the eyelashes. Mascara compositions of the invention reduce eyelash damage and though having low viscosity (as compared to typical prior art compositions) surprisingly provide excellent buildup, lengthening and wear. | 2011-04-14 |
20110085999 | USE OF AT LEAST ONE (DIHYDRO)JASMONIC ACID DERIVATIVE FOR TREATING DRY SKIN - A cosmetic process for treating dry skin and/or a dry scalp of non-inflammatory origin, for example, in a menopausal woman, comprising topically applying to the skin and/or the scalp a composition comprising, in a physiologically acceptable medium, at least one (dihydro)jasmonic acid derivative; novel (dihydro)jasmonic acid derivatives and to the compositions, for example, suitable for topical application to the skin, comprising them. | 2011-04-14 |
20110086000 | NOVEL SKIN PEEL COMPOSITION IN MASQUE FORM - The present invention is directed to a method of reducing the appearance of skin changes associated with intrinsic and/or extrinsic aging, involving the steps of: (a) providing a first composition containing: (i) from about 20 to about 50% by weight of at least one hydroxy acid; (ii) optionally, from about 1 to about 15% by weight of at least one weak organic acid; and (iii) remainder, to 100%, water; (b) providing a second composition containing: (iv) from about 20 to about 50% by weight of L-ascorbic acid powder; (v) optionally, from about 1 to about 10% by weight of an extract of | 2011-04-14 |
20110086001 | COMPLIANT BIOCOMPATIBLE POLYMER COMPOSITIONS FOR MEDICAL USES - Phase-separated elastomeric biocompatible polymer compositions are disclosed that are bioresorbable and/or biodegradable, and are useful in a variety of medical applications in which a low modulus polymer is desired, such as in the fabrication of medical devices. | 2011-04-14 |
20110086002 | RESTORATION OF HEARING LOSS - The present invention relates to compositions and methods for restoring hearing loss. In particular aspects, the invention relates to the administration of compositions that encode an inflammatory response control element. The compositions are prepared and administered in such a manner that the inflammatory response control element coding sequence is expressed in the subject to which the composition is administered. The compositions include expression systems, delivery systems, and certain inflammatory response control genes. | 2011-04-14 |
20110086003 | STABILIZATION OF HYDROPHOBIC PROTEIN THERAPEUTIC AGENTS - The present invention relates to a stabilized solution comprising a hydrophobic protein, a method for the production thereof, and the stabilizing solution as a pharmaceutical, and the use thereof. | 2011-04-14 |
20110086004 | METHODS OF TREATING CANCER USING IL-21 AND MONOCLONAL ANTIBODY THERAPY - Methods for treating cancer by co-administering a therapeutic monoclonal antibody with IL-21 are described. Exemplary monoclonal antibodies that can be used are rituximab, trastuzumab and anti-CTLA-4 antibodies. The enhanced antitumor of the combination therapy is particularly useful for patient populations that are recalcitrant to monoclonal therapy, relapse after treatment with monoclonal antibodies or where the enhanced IL-21 antitumor effect reduces toxicities associated with treatment using the monoclonal antibodies. | 2011-04-14 |
20110086005 | MODULATING INTERSTITIAL PRESSURE AND ONCOLYTIC VIRAL DELIVERY AND DISTRIBUTION - Provided herein are methods of treating a proliferative disorder in a subject comprising decreasing interstitial pressure and/or increasing vascular permeability in the subject and administering to the subject an oncolytic virus. Such methods improve oncolytic viral delivery and distribution. | 2011-04-14 |
20110086006 | HCV NS3-NS4 Protease Resistance Mutants - The present invention is directed to mutants of HCV NS3/4A protease. More particularly, the present invention identifies mutant of HCV NS3/4A protease that are resistant to drug treatment. | 2011-04-14 |
20110086007 | EPIDERMAL STIMULATION TO ENHANCE HAIR FOLLICLE FORMATION - The present invention features a method for improving the efficiency of hair formation by follicular cell implantation. The method includes the use of epidermal stimulation (ES) to stimulate keratinocytes in a subject's skin in order to make them more receptive to hair inductive signals originating from implanted follicular cells (e.g. dermal papilla cells, dermal sheath cells, and/or outer root sheath cells). | 2011-04-14 |
20110086008 | COMPOSITION AND METHOD FOR THE REPAIR AND REGENERATION OF CARTILAGE AND OTHER TISSUES - The present invention relates to a new method for repairing human or animal tissues such as cartilage, meniscus, ligament, tendon, bone, skin, cornea, periodontal tissues, abscesses, resected tumors, and ulcers. The method comprises the step of introducing into the tissue a temperature-dependent polymer gel composition such that the composition adhere to the tissue and promote support for cell proliferation for repairing the tissue. Other than a polymer, the composition preferably comprises a blood component such as whole blood, processed blood, venous blood, arterial blood, blood from bone, blood from bone-marrow, bone marrow, umbilical cord blood, placenta blood, erythrocytes, leukocytes, monocytes, platelets, fibrinogen, thrombin and platelet rich plasma. The present invention also relates to a new composition to be used with the method of the present invention. | 2011-04-14 |
20110086009 | Cell line for the production of prostacyclin and uses thereof - Provided herein are methods for producing a biomolecule by converting or engineering a plurality of cells, e.g., mammalian cells, having an endogenous precursor of a biomolecule to cells transfected to contain a nucleic acid that stably overexpresses a hybrid enzyme effective to metabolized the precursor to the biomolecule in the cell, e.g., prostacyclin produced from arachidonic acid. Also provided are methods of treating a pathophysiological condition associated with at least a decrease in the biomolecule or treating a vascular disease by administering the engineered, stably transfected mammalian cells to a subject where production of the biomolecule treats the condition or vascular disease. Further provided are the recombinant hybrid enzymes and the engineered cell lines and pharmaceutical compositions thereof, the nucleic acids encoding the hybrid enzymes, and vectors comprising the nucleic acids. | 2011-04-14 |
20110086010 | Methods, Systems, and Apparati for Cellular Therapeutic Agent Preparation and Delivery - Methods and devices for the preparation of a biological pharmaceutical composition outside of a classified environment, such as Biological Safety Cabinet type environment, are described. In one aspect of the present technology, a method is provided to prepare a biological pharmaceutical composition preferably in an area next to a patient's bedside or at a facility's pharmacy. The method comprises transferring an appropriate amount of a diluent from a diluent component ( | 2011-04-14 |
20110086011 | Prevention or Treatment of Immune-Relevant Disease by Modification of Microfloral Populations - The present invention is a method for preventing or treating an immune-relevant disease by modulating commensal microbiota populations via antibiotics, exogenous microbiota and/or probiotics. | 2011-04-14 |
20110086012 | Rejuvenation Method - A rejuvenation method includes a) removing blood or tissue from a human body or animal body, b) nurturing and purifying the blood or tissue, and c) implanting the blood or tissue that has been nurtured and purified into a user to increase the amount of stem cells in the user and to recover degraded organs in the user. Thus, the rejuvenation method is used to increase the number of the stem cells in the user successively so that the degraded organs in the user are repaired and recovered completely and can be returned to the optimum state so as to achieve the rejuvenation purpose. In addition, the blood or tissue is removed and taken from the user's body without causing a rejection. | 2011-04-14 |
20110086013 | ACYLGLYCEROL ACETYLTRANSFERASE-LIKE PROTEIN MGAT-X1 AND USES THEREOF - The present invention is directed to a polynucleotide sequence of a novel acylglycerol acyltransferase-like protein MGAT-X1. The invention also provides the human MGAT-X1 associated with the dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases. The invention also provides assays for the identification of compounds useful for the modulation of dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases for treating of such diseases associated with expression of the MGAT-X1. The invention also features compounds which bind to and/or activate or inhibit the activity of MGAT-X1 as well as pharmaceutical compositions comprising such compounds. | 2011-04-14 |
20110086014 | METHOD FOR ENZYMATIC CROSS-LINKING OF A PROTEIN - A method for cross-linking albumin for use as a sealant or glue for a biological system, for example to induce hemostasis and/or prevent leakage of any other fluid from a biological tube or tissue, such as lymph for example. The cross-linked albumin may optionally and preferably be applied as part of a bandage for example. In other embodiments, the present invention provides a method of enzymatically cross-linking globular proteins, by altering the structure of the protein to improve the accessibility of the protein to the cross-linking enzyme. | 2011-04-14 |
20110086015 | ZINC FINGER NUCLEASE FOR THE CFTR GENE AND METHODS OF USE THEREOF - The present invention provides new zinc finger proteins and zinc finger nuclease (ZFNs) that find particular using in repairing the cystic fibrosis transmembrane conductance regulator (CFTR) gene. | 2011-04-14 |
20110086016 | Enzymatic pre-mixture against Gram negative bacteria colonization in the animal intestinal tract - The invention provides pre-mixture for animal feeding comprising: (a) a polymer or a mixture of polymers, with a content in mannose comprised between 10% and 100%; (b) β-mannanase enzyme; and (c) an anti-binding agent; wherein the anti-binding agent has an absorptive capacity higher than 20%, and a bulk density which is comprised between 0.10 and 2.70 g/cm | 2011-04-14 |
20110086017 | Medical Food composition and methods for management of inflammatory processes in mammals - A medical food composition, containing at least source of milk protein derived from milk producing animals, exposed to immune stimulants during pregnancy and lactation period, source of Curcuminoids, source of proteolytic enzymes, and source of Piperin effective to manage inflammatory response and associated pain symptoms in mammals. | 2011-04-14 |
20110086018 | PROTEINASES DESTROY CANCER TUMOR'S SOLID STRUCTURE AND KILL CANCER CELLS LOCALLY - A proteinase therapy has been invented to eliminate solid tumors by destroying tumors' solid structure and killing cancer cells by cleaving vital extracellular matrix proteins C-terminally, N-terminally or both with cell membrane intact and limited adverse effects. The micro-scale intratumoral proteinase K therapy is tumor specific but not cancer type specific. Proteinase K therapy can be operated on multiple tumors on multiple occasions, if necessary. It may be employed to eliminate any solid tumor to prolong a cancer patient's life span. | 2011-04-14 |
20110086019 | POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS AND ANTAGONISTSMETHODS FOR - The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD. | 2011-04-14 |
20110086020 | Agent exhibiting immunoregulatory properties and the use thereof for treating autoimmune diseases - The invention relates to medicine. The inventive agent which exhibits immunoregulatory properties and accelerated clinical performance at a recrudescence stage and is mainly used for treating autoimmune diseases comprises trophoblastic β-1-glycoprotein and immunoglobulin (Ig) which is embodied in the form of a multivalent ligand G (Ig-G) or A (Ig-A) or M (Ig-M) immunoglobulin. According to the second invention, an agent for treating autoimmune diseases comprises β-1-glycoprotein and immunoglobulin (Ig-G), wherein the multivalent ligand G or A (Ig-A) is used in the form of an immunoglobulin and the β-1-glycoprotein and immunoglobulin (Ig-G) are taken in equal portions on in portions whose ratio is equal to 1:19, respectively. For treating autoimmune diseases, the agent containing β-1-glycoprotein and immunoglobulin (Ig) is parenterally administratable. | 2011-04-14 |
20110086021 | Sclerostin and the inhibition of WNT signaling and bone formation - The loss of the SOST gene product sclerostin leads to sclerosteosis characterized by high bone mass (HBM). In this report, we found that sclerostin could antagonize canonical Wnt signaling in human embryonic kidney A293 cells and mouse osteoblastic MC3T3 cells. This sclerostin-mediated antagonism could be reversed by over-expression of Wnt coreceptor LRP5. In addition, we found that sclerostin bound to LRP5 as well as LRP6 and identified the first two YWTD-EGF repeat domains of LRP5 as being responsible for the binding. Although these two repeat domains are required for transducing canonical Wnt signals, canonical Wnt did not appear to compete with sclerostin for binding to LRP5. Examination of the expression of sclerostin and Wnt7b, an autocrine canonical Wnt, during primary calvarial osteoblast differentiation revealed that sclerostin is expressed at the late stages of osteoblast differentiation coinciding with the expression of osteogenic marker osteocalcin and trailing after the expression of Wnt7b. Given the plethora of evidence indicating that canonical Wnt signaling stimulates osteogenesis, we believe that the HBM phenotype associated with the loss of sclerostin may at least in part be attributed to an increase in canonical Wnt signaling resulting from the reduction in sclerostin-mediated Wnt antagonism. | 2011-04-14 |
20110086022 | Methods for diagnosing and treating neuroendocrine cancer - The present invention relates to a method for diagnosing neuroendocrine cancers via detecting the presence of N-methyl D-asparate-associated (NMDA) glutamate receptors type 1 and/or type 2. Methods for preventing and treating neuroendocrine cancers are also disclosed. | 2011-04-14 |
20110086023 | COMBINATION ANTIHISTAMINE MEDICATION - The invention provides a topical pharmaceutical composition for application to the nasal or ocular mucosa which comprises (1) a pharmaceutical excipient suitable for topical administration, (2) a mucosal adjuvant, (3) an antihistamine drug and (4) a mast cell stabilizer, a non-steroidal anti-inflammatory drug, a phosphodiesterase inhibitor, an anti-IgE agent, heparin, a topical steroid or a leukotriene blocker. | 2011-04-14 |
20110086024 | USE OF ANTAGONISTS OF THE INTERACTION BETWEEN HIV GP120 AND A4B7 INTEGRIN - Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and α4 integrin, such as a α4β1 or α4β7 integrin antagonist, thereby treating the HIV infection. In several examples, the α4 integrin antagonist is a monoclonal antibody that specifically binds to a α4, β1 or β7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and α4 integrin, such as a α4β1 or α4β7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV. | 2011-04-14 |
20110086025 | Combination Therapy of a Type II Anti-CD20 Antibody with an Anti-BCL-2 Active Agent - The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and an anti-Bcl-2 active agent for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. | 2011-04-14 |
20110086026 | ANTIBODIES AGAINST IL-13 RECEPTOR ALPHA 1 AND USES THEREOF - An antibody binding to IL-13Rα1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of said antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9 is useful in the treatment of asthma and allergic diseases. | 2011-04-14 |
20110086027 | ANTI-CXCR4 ANTIBODIES - The present invention provides antibodies that bind human CXCR4 and are characterized as having high affinity and strong neutralizing properties. The antibodies of the invention are useful in the treatment of tumorigenesis, including tumor growth, invasion, angiogenesis, or metastasis. | 2011-04-14 |
20110086028 | PREVENTION OF HIV INFECTION - This invention relates to methods compositions and devices for inhibiting infection of a subject's host cell by HIV. Specifically, the invention relates to methods and compositions capable of inhibiting the binding and subsequent infection by HIV of a host cell through the inhibition of the interaction between gp-340 expressed on the cell surface and V3 loop on the HIV envelope and devices comprising these compositions. | 2011-04-14 |
20110086029 | NOVEL ANTIBODIES AGAINST CANCER TARGET BLOCK TUMOR GROWTH, ANGIOGENESIS AND METASTASIS - The present invention provides antibodies that target the first-third domains of N-cadherein and the fourth domain of N-cadherin, for diagnosis and therapy of cancers related to N-cadherein. Methods of diagnosis and treatment utilizing these antibodies are also described. | 2011-04-14 |
20110086030 | INHIBITION OF CANCER METASTASIS - The present invention provides methods for inhibiting tumor cell metastasis. In particular, the invention provides methods for reducing tumor cell malignancy by administering to a subject an antibody that inhibits glycoprotein Ibα, such that tumor cell malignancy is reduced. | 2011-04-14 |
20110086031 | Inhibition Of The Activity Of The Capsaicin Receptor In The Treatment Of Obesity Or Obesity-Related Diseases And Disorders - The present invention provides a method of treating diseases or disorders benefiting from inactivating or down-regulating the activity of the capsaicin receptor in a mammal by inhibiting the activity of the capsaicin receptor. The present invention also provides a method of treating obesity and obesity-related diseases and disorders in a mammal by inhibiting the activity of the capsaicin receptor. | 2011-04-14 |
20110086032 | ANTI-FGF19 ANTIBODIES AND METHODS USING SAME - The invention provides anti-FGF19 antibodies, and compositions comprising and methods of using these antibodies, methods using anti-FGF19 antibodies, and methods comprising detection of FGF19 and/or FGFR4. | 2011-04-14 |
20110086033 | METHOD OF INHIBITING OSTEOCLAST ACTIVITY - Methods for inhibiting osteoclastogenesis by administering a soluble RANK polypeptide are disclosed. Such methods can be used to treat a variety of different cancers, including bone cancer, multiple myeloma, melanoma, breast cancer, squamous cell carcinoma, lung cancer, prostate cancer, hematologic cancers, head and neck cancer and renal cancer. | 2011-04-14 |
20110086034 | NUCLEOTIDE AND PROTEIN SEQUENCES OF NOGO GENES AND METHODS BASED THEREON - The present invention relates to the gene, $i(Nogo), its encoded protein products, as well as derivatives and analogs thereof. Production of Nogo proteins, derivatives, and antibodies is also provided. The invention further relates to therapeutic compositions and methods of diagnosis and therapy. | 2011-04-14 |
20110086035 | IMMUNOTHERAPEUTIC METHODS AND MOLECULES - A peptide of less than 10 000 molecular weight comprising the amino acid sequence FHTYTI DWTKDAVTW or a portion thereof, or a variant thereof wherein the side chains of one or two of the amino acid residues are altered, wherein the portion or variant is capable of binding HLA-DRB1*04. The peptide, certain polypeptide fusion molecules and certain polynucleotides encoding the same may be useful in combating | 2011-04-14 |
20110086036 | COMPOSITION COMPRISING VLP AND AMYLOID BETA PEPTIDE - The present invention relates to novel uses of a construct consisting of virus-like particle (VLP) structure chemically coupled to a fragment of the A□-1-42 peptide and its pharmaceutically acceptable salts (hereinafter CONSTRUCT), in particular to dosage regimens, modes of and dosage forms for the administration of a CONSTRUCT for the treatment of patients suffering from dementia, in particular dementia of the A | 2011-04-14 |
20110086037 | METHOD OF TREATING INFLAMMATORY DISORDERS - A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms of formation of this particular pathological syndrome. | 2011-04-14 |
20110086038 | Interleukin-13 Antibody Composition - The invention relates to a pharmaceutical composition comprising an interleukin-13 antibody, more particularly a monoclonal interleukin-13 antibody, especially a human interleukin-13 monoclonal antibody, to a process for purifying said antibody and to the use of said composition in treating interleukin-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, chronic obstructive pulmonary disease, scleroderma, inflammatory bowel disease and Hodgkin's lymphoma, particularly asthma. | 2011-04-14 |
20110086039 | Methods of Treating Liver Fibrosis and Pre-Cirrhosis with Epidermal Growth Factor Receptor Inhibitors - This invention relates generally to a therapeutic use of epidermal growth factor receptor inhibitors to reduce fibrosis, e.g., liver fibrosis, or pre-cirrhosis in a subject. | 2011-04-14 |
20110086040 | METHOD OF TREATING HEMOLYTIC DISEASE - Paroxysmal nocturnal hemoglobinuria or other hemolytic diseases are treated using a compound which binds to or otherwise blocks the generation and/or the activity of one or more complement components, such as, for example, a complement-inhibiting antibody. | 2011-04-14 |
20110086041 | Fusion-Intermediate State of HIV-1 gP41 Targeted by Broadly Neutralizing Antibodies - Isolated, antigenic polypeptides including a prehairpin intermediate conformation of gp41 and vectors encoding such polypeptides are provided. Antibodies that bind to a prehairpin intermediate conformation of gp41 and methods of making antibodies a that bind to prehairpin intermediate conformation of gp41 are also provided. Vaccines against a prehairpin intermediate conformation of gp41, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided. Methods of screening compounds that bind to an isolated, prehairpin intermediate conformation of gp41 are further provided. | 2011-04-14 |
20110086042 | Centrosomal Proteins, Nucleic Acids and Method of Use Thereof - The present invention provides novel isolated centrobin polynucleotides and polypeptides encoded by the centrobin polynucleotides. The invention additionally provides methods of inhibiting cell growth by contacting a cell with a centrobin inhibitor. | 2011-04-14 |
20110086043 | STAT5a AND ITS FUNCTIONAL TUMOR SUPPRESSOR ANALOGS FOR TREATMENT OF MALIGNANCIES EXPRESSING NPM/ALK AND OTHER ONCOGENIC KINASES - The invention provides methods of inhibiting epigenetic gene silencing in a cell expressing NPM/ALK or decreasing NPM/ALK content in a cell, by contacting a cell with an agent capable of increasing the concentration of Stat5a protein or its functional analog. Further, the invention provides a method of treating malignancies expressing oncogenic kinase by administering to a patient affected with a malignancy an agent capable of increasing the concentration of Stat5a protein or its epigenetically silenced functional tumor suppressor analog in a malignant cell. Finally, it provides a method to diagnose malignancy and monitor patient's response to therapy by analysis of the degree of DNA methylation of the gene encoding for Stat5a or its analog, their mRNA, or protein. | 2011-04-14 |
20110086044 | Compositions and Methods to Inhibit HPV Infection - This invention provides compositions and method for inhibiting and treating an HPV infection of LC or tissue containing LC by administering to the LC or tissue an effective amount of an agent that inhibits HPV binding to annexin A2 (ANXA2) present on the surface of the cell, thereby inhibiting HPV infection. It also provides methods to design antiviral and/or anticancer agents for cancers that harbor HPV. | 2011-04-14 |
20110086045 | METHOD FOR ENHANCING GROWTH OR INCREASING FEED EFFICIENCY THROUGH REDUCING BINDING BETWEEN ENDOTOXIN AND ITS RECEPTOR IN THE GASTROINTESTINAL TRACT - A method for reducing gastrointestinal inflammation, enhancing growth, or improving feed efficiency in a human or non-human animal is disclosed. The method involves administering to the animal an agent that can reduce the formation of the signal transduction complex of endotoxin, TLR4 and CD14 on the cellular surface of a cell in the gastrointestinal tract of the animal. In a preferred embodiment, an antibody against the extracellular domain of TLR4 or CD14 is used to reduce the formation of the complex. A composition that contains the antibody and an ingestible carrier is also disclosed. Further disclosed is a method for producing a peptide for enhancing growth, improving feed efficiency, or both in a human or non-human animal. | 2011-04-14 |
20110086046 | Treatment of MS with goat serum - A serum composition from a goat immunised with HIV contains anti-HLA antibody and is suited for palliative improvement of the condition of an animal. | 2011-04-14 |
20110086047 | FC RECEPTOR HOMOLOG ANTIBODIES AND USES THEREOF - Provided herein are antibodies having the same epitope specificity as an antibody produced by the hybridoma cell line deposited with the American Type Culture Collection as hybridoma 4-2A6, 1-5A3, or 1-3B4. Further provided herein are methods of identifying and selecting cells that express FcRH1 or FcRH4. Methods of diagnosing and treating a subject with a malignancy of a hematopoietic cell lineage or an autoimmune disease and methods of modulating a humoral immune response in a subject are also provided herein. Further provided herein are polypeptides comprising one or more complementary determining regions of the disclosed antibodies and nucleic acids that encode the disclosed polypeptides. | 2011-04-14 |
20110086048 | DETECTION OF HUMAN IMMUNODEFICIENCY VIRUS CO-RECEPTOR TROPISM IN AVIREMIC SUBJECTS - Methods for detecting human immunodeficiency virus (HIV) co-receptor tropism or replication-competent virus in aviremic subjects, and methods of selecting optimal therapies for aviremic subjects. | 2011-04-14 |
20110086049 | Receptor Modulators - Method of identifying a modulator of CD28 comprising comparing a structural model of a candidate modulator with a structural model of CD28 to thereby determine whether the modulator will bind to CD28, wherein the structural model is derived from, or comprises, structural coordinates of a crystal of: (i) CD28, (ii) a fragment of CD28, or (iii) a homologue of (i) or (ii). The crystal of CD28 in a soluble form complexed with the Fab fragment of a mitogenic (superagonistic) antibody has been obtained and used for the determination of the 3D-structure of the receptor. The application also relates to modulators of superagonistic signalling for any receptor of the CD28 family, i.e. to superagonistic antibodies and chimeric proteins thereof, and to the screening of the superagonistic modulators. In the methods of screening, the binding of the candidate modulators to a portion of the receptor proximal to the cell membrane is investigated. | 2011-04-14 |
20110086050 | GLYCOPROTEIN COMPOSITIONS - The present invention concerns compositions comprising a glycoprotein having an Fc region, wherein about 80-100% of the glycoprotein in the composition comprises a mature core carbohydrate structure which lacks fucose, attached to the Fc region of the glycoprotein. The preferred glycoprotein is an antibody or immunoadhesin. | 2011-04-14 |
20110086051 | SYSTEM AND METHOD FOR MONITORING AND OPTIMIZING IMMUNE STATUS IN TRANSPLANT RECIPIENTS - This invention provides a system and method for an assay used in determining appropriate immunosuppressant levels relative to organ transplant in which PBMC is separated from whole blood by Ficoll®. An aliquot of PBMC is used for phenotyping of cells. CD4, CD8, memory and naïve subsets, B-cells regulatory T-cells and other cell markers (e.g. CD31) are examined. After an aliquot of PBMC is taken, CD4 cells are isolated. DNA is isolated from the cells. CD4 cells can be used for TREC at the defined time points. The TREC assay can be performed via a validated protocol. TREC levels are then measured using a quantitative RT-PCR for single jointed TREC. Alternatively, or additionally, TREC-correlated cell markers (e.g. CD31) can be analyzed. Approximately 100,000 cells, or 2 micrograms, of DNA are desired for TREC analysis. Normal control cells are run in parallel. A kit for performing the assay, including instructions and various components can be provided for practitioners. | 2011-04-14 |
20110086052 | ACTIVATION OF INNATE AND ADAPTIVE IMMUNE RESPONSES BY A GINSENG EXTRACT - The invention is directed to ginseng fractions and methods for activating innate and adaptive immune responses to prevent, treat or ameliorate a condition in a subject by administering to the subject an effective amount of a ginseng traction, a pharmaceutical composition comprising the fraction in combination with another medicament or with one or more pharmaceutically acceptable carriers, or a food item comprising the fraction. The fraction may be made from | 2011-04-14 |
20110086053 | Glycolipids And Analogues Thereof As Antigens For NKT Cells - This invention relates to immunogenic compounds which serve as ligands for NKT (natural killer T) cells and to methods of use thereof in modulating immune responses. | 2011-04-14 |
20110086054 | YEAST STRAIN FOR THE PRODUCTION OF PROTEINS WITH TERMINAL ALPHA-1,3-LINKED GALACTOSE - Lower eukaryotic host cells have been engineered to produce glycoprotein having at least one terminal α-galactosyl epitope. The glycoproteins are useful for the production of highly antigenic glycoprotein compositions with advantages for the production of vaccines. | 2011-04-14 |
20110086055 | HER2 PEPTIDES - Compositions, methods, and vaccines that may stimulate the immune system and that may be used for treating malignancies associated with overexpression of the HER-2 protein are provided. Such compositions include epitopes of the HER-2 proteins. | 2011-04-14 |
20110086056 | Methods for the early diagnosis of ovarian cancer - The present invention discloses the protease hepsin is specifically over-expressed in ovarian and other malignancies. A number of hepsin peptides can induce immune responses to hepsin, thereby demonstrating the potential of these peptides in monitoring and the development of immunotherapies for ovarian and other malignancies. There is also provided a hepsin protein variant that is useful as a marker for ovarian cancer cells, prostate cancer cells or kidney cancer cells. | 2011-04-14 |
20110086057 | OX40R Binding Agents - The present invention discloses peptides isolated from the extracellular domain of OX40 Ligand (OX40L) capable of binding OX40 Receptor (OX40R) and inhibiting OX40R-OX40L interaction. Such peptides, fusion proteins comprising them, as well as peptides and other molecules designed on their sequences, can be used as OX40R binding agents competing with natural OX40L for blocking OX40R-mediated cell signaling in the prophylaxis and/or treatment of diseases related to activated T cells. | 2011-04-14 |
20110086058 | Immunopotentiator-Linked Oligomeric Influenza Immunogenic Compositions - Disclosed herein are immunogenic compositions for preventing infection with influenza viruses wherein the immunogenic compositions comprises an immunogen such as a hemagglutinin of an influenza virus, and an immunopotentiator such as an Fc fragment of human IgG and optionally a stabilization sequence. The immunogen is linked to the stabilization sequence which in turn is linked to the immunopotentiator. | 2011-04-14 |
20110086059 | NON-HEMOLYTIC CLYA FOR EXCRETION OF PROTEINS - The disclosure below provides a protein export system utilizing non-hemolytic variants of HlyE family member proteins for efficiently producing recombinant protein from a host cell. In a preferred embodiment, the protein export system utilizes protein export machinery endogenous to the host bacterium into which the protein export system vector is introduced. | 2011-04-14 |
20110086060 | NOVEL COMPOSITIONS AND THEIR USE - The present invention relates to a composition comprising panthenol, a collagen synthesis stimulating peptide and an anti-inflammatory extract. The compositions are particular useful for preventing and treating stretch marks. | 2011-04-14 |
20110086061 | Cancer Detection Methods and Reagents - The present invention comprises methods and compositions for detecting cancer in an individual comprising autoantibodies to cancer-associated antigens. Specifically, the present invention comprises methods and compositions for detecting autoantibodies to cancer-associated antigen in a bodily fluid as well as use of said autoantibodies as a means to detect the presence of cancer-associated antigens. | 2011-04-14 |
20110086062 | ALPHAVIRUS REPLICON PARTICLES MATCHED TO PROTEIN ANTIGENS AS IMMUNOLOGICAL ADJUVANTS - The immune response to an antigen of interest, especially one in purified form, can be significantly enhanced by the simultaneous administration of an alphavirus replicon particle which expresses the same antigen. This allows for the use of significantly smaller quantities of the protein antigen than in conventional immunization strategies, and this new immunization strategy can also eliminate the need for boosting administration of the antigen or it can reduce the number of boosts required for an effective immune response to the antigen. | 2011-04-14 |
20110086063 | VACCINES FOR PREVENTION AND TREATMENT OF ADDICTION - The invention provides an adenovirus-antigen conjugate comprising an adenovirus with a coat protein and an antigen of an addictive drug conjugated to the coat protein of the adenovirus. The invention also provides an adenoviral vector comprising a nucleic acid sequence which encodes an antibody directed against the addictive drug. The invention further provides a method of inducing an immune response against an addictive drug or reducing the effect of an addictive drug in a human by ad-ministering to the human the aforementioned adenovirus-antigen conjugate or antibody encoding adenoviral vector. | 2011-04-14 |
20110086064 | COMPOSITIONS AND METHODS FOR IDENTIFYING AND TARGETING CANCER CELLS OF ALIMENTARY CANAL ORIGIN - Screening and diagnostic reagents, kits and methods for metastatic colorectal cancer or primary and/or metastatic stomach or esophageal cancer are disclosed. Vaccines compositions and methods of for treating and preventing metastatic colorectal cancer or primary and/or metastatic stomach or esophageal cancer are disclosed. | 2011-04-14 |
20110086065 | Lentival Vector-Based Vaccine - Methods of eliciting humoral responses, methods of immunization, and methods of vaccination using lentiviral vector are disclosed. Additionally, immunogenic compositions and vaccines for West Nile Virus are disclosed. | 2011-04-14 |
20110086066 | Methods to Increase Transgene Expression From Bacterial-Based Delivery Systems by Co-Expressing Suppressors of the Eukaryotic Type I Interferon Response - Bacterial delivery systems with improved transgene expression are provided. The recombinant bacterial delivery systems deliver transgenes of interest and suppressors of the eukaryotic Type I interferon response to eukaryotic cells. Suppression of the eukaryotic Type I interferon response allows improved expression of the encoded transgene. | 2011-04-14 |
20110086067 | ANTITUMOR VACCINATION USING ALLOGENEIC TUMOR CELLS EXPRESSING ALPHA (1,3)-GALACTOSYLTRANSFERASE - The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an α(1,3)galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The α-galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal. | 2011-04-14 |
20110086068 | Compositions and Methods for Tissue Engineering, Tissue Regeneration and Wound Healing - In accordance with certain embodiments of the present disclosure, a kit is described. The kit includes primed living cells joined to and at least partially within a three-dimensional hydrogel structure and an isolated polypeptide having the carboxy-terminal amino acid sequence of an alpha Connexin, or a conservative variant thereof, wherein the polypeptide does not include the full length alpha Connexin protein. | 2011-04-14 |
20110086069 | PHARMACEUTICAL FORMULATIONS OF NITRITE AND USES THEREOF - The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO | 2011-04-14 |
20110086070 | Orally disintegrating compositions of rhein or diacerein - The invention relates to orally disintegrating pharmaceutical compositions comprising rhein or diacerein, or salts or esters or prodrugs thereof, and processes for preparing such compositions. | 2011-04-14 |
20110086071 | Pharmaceutical Compositions Comprising Terbinafine - This invention provides a terbinafine pharmaceutical composition which is emulsifable or self-emulsifying or in form of an emulsion wherein the composition is adapted for oral administration. | 2011-04-14 |
20110086072 | Treatment of Mammalian Physiological Reaction of IgE Antibodies Present in Said Mammal Upon Contact With the Corresponding Antigen - A method is disclosed for blocking or reducing physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) derived from | 2011-04-14 |
20110086073 | NANOMETER-SIZED PRODRUGS OF NSAIDs - The present invention describes nanoprodrugs of non-steroidal anti-inflammatory drug (NSAIDs) and nanoprodrugs of α-lipoic acid-containing and NSAIDs. These nanoprodrugs have antioxidant properties and stimuli-responsiveness, which can be used to treat various disease conditions. | 2011-04-14 |
20110086074 | COMBINATIONS OF NIACIN AND AN OXICAM - Pharmaceutical formulations comprising a combination of niacin and an oxicam NSAID, for oral administration, and methods of preparing the formulations. | 2011-04-14 |
20110086075 | PERSONAL CARE SUNSCREEN COMPOSITIONS HAVING REDUCED EYE IRRITATION - The present invention is directed to a stable, minimal energy required self-assembling lamellar and spherulite composition comprising: mixture water, fatty alcohol, fatty acid, salt of fatty acid, polyglyceryl fatty acid ester and oils. The present invention relates to composition that can benefit eye mildness, even distribution of sunscreen physical filters on skin and enhanced stability. | 2011-04-14 |
20110086076 | COMPACT POWDER FOR SKIN CARE OR FOR MAKING UP THE SKIN - The subject of the present invention is a compact powder which is soft and creamy on application, and which contains a filler composed of a substrate in the form of platelets, arranged at the surface of which are particles which have an average size of between 5 nm and 10 μm and a refractive index of less than 2. | 2011-04-14 |
20110086077 | SILICONE HYDROGELS FOR TISSUE ADHESIVES AND TISSUE DRESSING APPLICATIONS - A silicone hydrogel formulation may contains random and/or block copolymers or oligomers or macromers. The silicone copolymer is copolymerized or blended with other polymers or monomers or macromers to obtain final formulation. The silicone hydrogel may contain crosslinking groups to provide a complete or partially crosslinked final structure. The silicone hydrogel formulation may be pre-formed as a film or other structure, or it may be polymerized during application as in the case of an adhesive formulation. A wound dressing comprising a silicone hydrogel formed as a film, either prior to application to a wound or in situ on a wound, which film has gas permeability, moisture permeability, and high water content, wherein said silicone hydrogel is formed from a polymerizable silicone such as a difunctional polydimethylsiloxane methacrylate and crosslinking agents such as N,N-dimethyllacrylamide (DMA), 2-hydroxyethyl methacrylate (HEMA), and trimethylsiloxy silane (TRIS). | 2011-04-14 |
20110086078 | FIBROUS ANTIMICROBIAL MATERIALS, STRUCTURES, AND BARRIER APPLICATIONS - Fibrous antimicrobial materials for use in structures and barrier applications, such as face masks and wound dressings, have been developed from antimicrobial polymeric materials. The fibrous antimicrobial materials also are particularly suitable for use in air and water filtration. The antimicrobial polymeric materials are prepared from solid solutions of antimicrobial bisguanide compounds blended with certain thermoplastic polymers. The antimicrobial polymeric materials may be extruded into fibers or used in the particulate form for preparation of the nonwoven antimicrobial materials. The antimicrobial bisguanide compound, such as chlorhexidine, are distributed at the molecular level within at least one thermoplastic polymer, such as a polyolefin in which the antimicrobial bisguanide compound is soluble, to form a miscible blend. Methods for their formation and use also are provided. | 2011-04-14 |
20110086079 | Methods for Producing Hair Microfollicles and De Novo Papillae and Their Use for In Vitro Tests and In Vivo Implantations - The present invention relates to a method for producing hair microfollicles comprising the steps of: a) providing de novopapillae, b) providing other cell populations selected from the group of fibroblasts, keratinocytes and melanocytes, and co-culturing the de novopapillae with at least one other cell population in non-adherent culture vessels. The present invention relates also to methods of producing de novo papillae usable in said method for producing hair microfollicles. | 2011-04-14 |
20110086080 | EX-VIVO PRODUCTION OF HUMAN DEMINERALIZED BONE MATRIX - The present disclosure provides ex vivo-derived human demineralized bone matrix. The bone matrix is produced using mineralized three-dimensional bone constructs. The bone constructs are obtained by culturing osteoblasts and osteoclast precursors under randomized gravity vector conditions. Preferably, the randomized gravity vector conditions are obtained using a low shear stress rotating bioreactor, such as a High Aspect Ratio Vessel (HARV) culture system. The ex vivo-derived human demineralized bone matrix of the disclosure can be used in, for example, orthopedic and periodontal procedures. | 2011-04-14 |
20110086081 | COATING SYSTEM AND METHOD FOR DRUG ELUTION MANAGEMENT - The teachings are directed to a medical device having a drug-retaining coating that at least substantially delays the initial elution of a drug for a time effective at forming a functional endothelium over a surface of the medical device. | 2011-04-14 |
20110086082 | COMPOSITION, SYSTEM, AND METHOD FOR MODULATING RELEASE KINETICS IN IMPLANTABLE DRUG DELIVERY DEVICES BY MODIFYING DRUG SOLUBILITY - An implantable drug delivery device loaded with a beneficial agent is provided, wherein the beneficial agent is in two different forms, a first form having a higher solubility and a second form having a lower solubility, and wherein the two different forms are present in a proportion which is selected to achieve a desired release rate. | 2011-04-14 |
20110086083 | IMPLANT DEVICES FOR MODULATING BIOACTIVE AGENT RELEASE PROFILES - Described herein are implant devices comprising at least one exposed biodegradable inner core surface, the inner core being surrounding partially by a membrane sheath which comprises a biocompatible polymer. A bioactive agent can be released from the inner core. | 2011-04-14 |
20110086084 | Active Agent Containing Polymer Network Delivery Composition and Articles Using the Same - Delivery compositions and substrates for imparting a volatile active agent to a surface are disclosed herein. To achieve the delivery of the volatile component, a delivery composition of a polymer network and a volatile component incorporated into the polymer network to stabilize the volatile for extended periods of time. The delivery composition may also be present on a substantially dry substrate to deliver the active agent. The dry substrate may be selected from facial tissue, bath tissue, paper towel, or dinner napkin. The substantially dry substrate may also be reusable. | 2011-04-14 |
20110086085 | Carbohydrate Entrapped Active Agent Delivery Composition and Articles Using the Same - Delivery compositions and substrates for imparting a volatile active agent to a surface are disclosed herein. To achieve the delivery of the volatile component, a delivery composition of a carbohydrate matrix and a volatile component is incorporated into the carbohydrate matrix to stabilize the volatile for extended periods of time. The delivery composition further comprises a self-generating expelling agent to expel the volatile component onto the contaminated surface or skin upon addition of a triggering agent. | 2011-04-14 |
20110086086 | TRANSDERMAL SYSTEM FOR VARENICLINE - The invention provides transdermal compositions comprising varenicline or its pharmaceutically acceptable salt or prodrug form. | 2011-04-14 |
20110086087 | Process and Formulation for Immunizing Fish in Aquaculture Systems - Process, use, method and formulation of inclusion of Deoxyribonucleic acid (DNA) in food compositions for livestock animals, in particular in aquacultural systems. | 2011-04-14 |
20110086088 | Compositions and methods for treatment of mammalian skin - Compositions useful for treatment of a wide range of skin disorders including: pre-cancerous lesions, keratotic lesions, superficial basal cell carcinomae; squamous cell carcinomae; malignant melanoma, and radiation-induced burns. In some embodiments the treatments comprise contacting human or other mammalian skin with a composition according to the disclosure. In other embodiments, administration of compositions provided is by injection. Some embodiments provide for preventive use of compositions provided towards preventing some forms of skin cancer and skin cancer-related disorders by repeated application to healthy-looking skin. Methods for providing the compositions are disclosed. | 2011-04-14 |
20110086089 | USE OF P27KIP1 FOR THE PREVENTION AND TREATMENT OF HEART FAILURE | 2011-04-14 |
20110086090 | Vectors Containing the Max Gene - The present invention refers to the construction of cloning vectors containing the max gene. Especially, the present invention refers to the introduction of cloning vectors containing the max gene in cells using transport vectors. In addition, the presence of cloning vectors containing the max gene in cells allows the differential expression of the max gene in the same cells. In addition, the present invention refers to a method of gene therapy in which the differential expression of the max gene has cytoprotective activity, especially neuroprotective activity, and is capable of application to medical and veterinary therapeutics of neurodegenerative conditions. | 2011-04-14 |
20110086091 | STABLE CRYSTAL MODIFICATIONS OF DOPC - The invention relates to stable crystal modifications of (R,S)-, (R)- and ( | 2011-04-14 |
20110086092 | PHARMACUETICAL TABLETS CONTAINING A PLURALITY OF ACTIVE INGREDIENTS - Described are stable compressed pharmaceutical dosage forms, such as tablets, layered so that incompatible active ingredients can be included in a single dosage form, and such that carry-over and intermixing are minimized in the manufacture process. | 2011-04-14 |
20110086093 | METHOD FOR INCREASING LACTOSE TOLERANCE IN MAMMALS EXHIBITING LACTOSE INTOLERANCE - The method for increasing lactose tolerance in subjects exhibiting lactose intolerance symptoms implements a protocol where the subjects ingest a gradually increasing amount of lactose containing product over a six week period. At various points during the six week period the subject ingests the lactose containing product once a day and then twice a day. The lactose containing product can be in liquid form, such as for example, milk, and is preferably in a powder form which is taken either by ingesting capsules having the lactose powder or in a granular form mixed with water or other non-lactose containing liquid. At the end of the six week period, the subject's tolerance for lactose containing products is substantially increased, with the potential of eliminating the subject's lactose intolerant behavior indefinitely, | 2011-04-14 |
20110086094 | CAPSULE FOR THE PREVENTION OF CARDIOVASCULAR DISEASES - The invention relates to a capsule for the prevention of cardiovascular diseases which comprises coated tablets of acetylsalicylic acid, coated tablets of simvastatin or pravastatin, and coated tablets of lisinopril, ramiphl or perindopril. The capsules are used for the prevention of cardiovascular diseases in high-risk populations. | 2011-04-14 |
20110086095 | Bioadhesive Polymers - Polymers and compositions, collectively “bioadhesive materials”, with improved bioadhesive properties have been developed. One or more compounds comprising: a) an aromatic moiety comprising two or more hydroxyl substituents, methoxy substituents, substituents hydrolyzable to hydroxyl substituents, or a combination thereof, and b) a primary or secondary amino moiety are either covalently attached to a polymer or are physically mixed with a polymer to form a bioadhesive material. These bioadhesive materials can be used, for example, to fabricate new drug delivery or diagnostic systems with increased residence time at tissue surfaces, and consequently increase the bioavailability of a drug or a diagnostic agent. | 2011-04-14 |
20110086096 | MODIFIED RELEASE 1- [ (3-HYDROXY-ADAMANT-1-YLAMINO)-ACETYL] -PYRROLIDINE-2 (S) -CARBONITRILE FORMULATION - The subject invention provides a pharmaceutical tablet formulation comprising per unit dosage form e.g. per tablet the following ingredients:
| 2011-04-14 |
20110086097 | Manufacture process for the preparation of an iron containing phosphate adsorbent - The present invention relates to a new manufacture process for producing an iron containing phosphate adsorbent, in particular to a process for manufacturing and isolating an iron(III)-based phosphate adsorbent which exhibits valuable pharmacological properties. | 2011-04-14 |